Rafael Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended July 31, 2023
October 30, 2023 at 04:14 pm EDT
Share
Rafael Holdings, Inc. reported earnings results for the fourth quarter and full year ended July 31, 2023. For the fourth quarter, the company reported sales was USD 0.068 million compared to USD 0.069 million a year ago. Net income was USD 1.16 million compared to net loss of USD 4.78 million a year ago. Basic earnings per share from continuing operations was USD 0.06 compared to basic loss per share from continuing operations of USD 0.24 a year ago. Basic earnings per share was USD 0.06 compared to basic loss per share of USD 0.24 a year ago.
For the full year, sales was USD 0.279 million compared to USD 0.29 million a year ago. Revenue was USD 0.279 million compared to USD 0.41 million a year ago. Net loss was USD 1.88 million compared to USD 124.66 million a year ago. Basic loss per share from continuing operations was USD 0.36. Basic loss per share was USD 0.08 compared to USD 6.31 a year ago.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Companyâs real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).